Elevate Your Imaging Practice with Comprehensive Risk Assessment 

The Ambry CARE Program® (CARE) empowers imaging centers to identify high-risk patients who need additional screening and preventive care. Our digital platform automates breast cancer risk assessment and hereditary cancer testing qualification, helping you provide personalized, proactive care for every patient.

Are You Missing High-Risk Patients?

The Challenge:

93% of women who qualify for high-risk breast MRI based on medical/family history never have one.1,2 
~5% of individuals have a mutation in a cancer predisposition gene, but most don't know it.3 
Paper-based risk assessment is inconsistent and often incomplete.4 
Complex, evolving testing guidelines can be difficult to interpret and apply manually.  

Deliver Personalized Care While Streamlining Your Workflows

With CARE (“Comprehensive Assessment of Risk & Education”), your imaging center can:

Identify more high-risk patients through universal Tyrer-Cuzick scoring and automated hereditary cancer genetic testing qualification using the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®️).5,6

Streamline workflows with digital patient history collection, assessment, and genetic test ordering that integrates with your EHR.

Facilitate personalized care plans based on breast cancer risk scores and genetic test results.

Improve early detection with support to identify patients
who qualify for advanced screening like breast MRI.

Connect patients with education resources
and telehealth genetic counseling.

Trusted by Leading Imaging Centers

dr-jenna-cooke-2025

"The transition to the Ambry CARE Program® improved our clinic workflows. More importantly, our program is changing patient lives because we can individualize their care based on their history and DNA."

Jenna Cooke, DNP, APRN, FNP-C, CGRA - Midstate Radiology Associates

dr-keller-2025

“The Ambry CARE Program appealed to me because LMI can easily determine the TC breast cancer risk score for each patient and know if she qualifies for genetic testing. Other solutions we've considered are very cumbersome or expensive, but not CARE.”

Cathrine Keller, MD – Lake Medical Imaging

How CARE Works

CARE_ImagingCenter_HxCollection_400x400

Digital History Collection

Patients complete medical and family history questionnaires via text or email before appointments. 

CARE_ImagingCenter_RiskAssessment_400x400

Automated Risk Assessment

CARE calculates Tyrer-Cuzick scores for all patients and evaluates hereditary cancer risk against NCCN Guidelines ®️.5,6 The assessment has been validated with 99.5% accuracy for hereditary cancer risk assessment using NCCN Guidelines.5,6,7 TC score can account for breast density.

CARE_ImagingCenter_PTEducation_400x400

Patient Education 

Digital resources help patients understand their risk factors, genetic testing, and how results could affect their care and their families.

CARE_ImagingCenter_GeneticTesting_400x400

Streamlined Genetic Testing

If medically necessary, providers can order genetic testing through the CARE platform.

CARE_ImagingCenter_ResultDelivery_400x400

Results Delivery

Test results are delivered securely to providers and patients through the CARE platform.

CARE_ImagingCenter_GeneticCounseling_400x400

Post-Test Genetic Counseling

Genetic counseling is available via telehealth to all patients.

CARE_ImagingCenter_Documentation_400x400
Documentation 

Transparency at each step, improving the experience for providers and patients.

Radiology2_488x300

Backed by Clinical Research

CARE’s clinical impact has been validated through rigorous research. A study presented at the San Antonio Breast Cancer Symposium (SABCS) examined outcomes when CARE was introduced to several breast and imaging centers:8

  • Assessment of 250,000 female patients over a 2-year period
  • Approximately 1 in 10 female patients received an updated cancer risk management plan
  • 13% of patients had elevated Tyrer-Cuzick scores (≥20%) and qualified for breast MRI
  • 42% of positive genetic test results had direct impact on breast care recommendations 

This research confirms that breast and imaging centers can use CARE as a scalable solution to identify patients who benefit from personalized risk assessment and management.

Real Results from an Imaging Center Using CARE

Midstate Radiology Associates Achieved: 

  • 400% increase in patients identified for screening breast MRI
  • 60% increase in qualified patients electing to have genetic testing
  • 76% completion rate for digital risk assessments
  • Nearly half of patients with positive genetic results had a shift in breast cancer risk management

"My sister died of breast cancer that was diagnosed at stage IV. My breast cancer was caught early, and I am so grateful for that. Without this program, my story could have been completely different."

Angie Butler - MRA CARE Patient identified as high-risk based on breast cancer risk score

Transform Your Practice with CARE

Implementing CARE at your imaging center means:

For Patients

Support them with personalized care plans that promote earlier detection and may reduce their cancer risk.

For Providers

Streamline your workflows, automate documentation, and leverage tools that will support you in providing guideline-concordant care. 

For Your Practice

Consistently connect qualified patients with high-risk services, improve patient satisfaction, and differentiate from competitors. 

Ready to Elevate Your High-Risk Screening Program?

Additional Resources

References

  1. Miles R, et aI. (2018) PMID: 29341851
  2. Hill, D. A., et al. (2017). https://doi.org/10.1007/s11606-017-4224-6
  3. Caswell-Jin, J. L., et al. (2019). https://doi.org/10.1093/jnci/djy147
  4. Wildin, R. S., et al. (2021). https://doi.org/10.1007/s12687-021-00531-6
  5. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. V3.2025. ©National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed March 6, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  6. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric. V3.2024. ©National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed March 6, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  7. Fecteau, H., Pfleger, H., Nathan, D., Siddiqui, S., Horton, C., Pilarski, R., Ryan, E., Thrush, D., Ranola, J., Clifford, J., Lyon, L., & Kieran, S. (in press). Validation of a digital tool that uses national testing guidelines to identify individuals at risk for hereditary cancer. JNCCN: Journal of the National Comprehensive Cancer Network. [Publication date, URL].
  8. Fecteau, H., Keller, H., Horton, C., Milliard, C., Pilarski, R., Lyon, L., Hoang, L., & Kieran, S. (2022, December). Expanding the reach of germline genetic testing: Use of web-based risk assessment to inform medical management amongst patients at breast and imaging centers. Poster presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, United States. 

 

Ambry_logo_Tempus_RGB

Questions? Contact Us.

info@ambrygen.com  (949) 900-5500